Business
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into Systemic
About this update from Cogent Biosciences, Inc.
[{"type":"text","content":"Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients\n Company on track to advance CGT9486 into Systemic Mastocytosis patients in 1H21\n Abstract selected for oral presentation at CTOS 2020\n New data from the Phase 1/2 clinical trial of CGT9486 in combination with sunitinib in patients with advanced GIST to be presented\n\n\nCAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. (\"Unum\") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its name change to Cogent Biosciences, Inc. (\"Cogent\"). Beginning on October 6, 2020, Cogent will trade on NASDAQ under the ticker symbol \"COGT\", and Cogent's common stock will trade under a new CUSIP number, 19240Q102. The new name reflects Cogent's mission to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Cogent is also pleased to provide an update on recent scientific and operational progress since its July acquisition of Kiq LLC, including the announcement of an upcoming oral presentation of Phase 1/2 clinical data in gastrointestinal stromal tumors (GIST) with Cogent's lead asset, PLX9486, at the 2020 Connective Tissue Oncology Society (CTOS) Annual Meeting to be held virtually November 18 – 21. In connection with the change of the Company's corporate name, Cogent anticipates that the name of PLX9486 will be changed to CGT9486.\n\n \n \n \n \n \n \n\n \n\"Our new name reflects the evolution of our company to focus on developing precision therapies for genetically defined diseases and paves the path forward as we strive to deliver real solutions for patients in serious need of new treatment options,\" said Chuck Wilson, PhD, President and CEO of Cogent. \"Over the past three months, we have made significant progress in shifting the focus of the company to align with our future vision, and we look forward to presenting additional data on our lead program PLX9486 at CTOS 2020 as we continue to make progress in advancing the program for the treatment of patients suffering from Systemic Mastocytosis and GIST.\" \nCogent remains on track to advance PLX9486 as a single agent in Advanced Systemic Mastocytosis patients in the first half of next year and Indolent Systemic Mastoc...